Detalhe da pesquisa
1.
High Level of CD8+PD-1+ Cells in Patients with Chronic Myeloid Leukemia Who Experienced Loss of MMR after Imatinib Discontinuation.
Cells
; 13(8)2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38667336
2.
A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry.
Am J Hematol
; 92(7): E125-E128, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28376561
3.
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Leukemia
; 35(2): 440-453, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33414482
4.
Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study.
Clin Lymphoma Myeloma Leuk
; 17(5): 283-295, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28185798
5.
The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience.
Dis Markers
; 2016: 7531472, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27818567
6.
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Leukemia
; 35(7): 2142-2143, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34108614
7.
Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
Leuk Lymphoma
; 56(8): 2309-14, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25563556
8.
Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry.
Clin Lymphoma Myeloma Leuk
; 18(7): e283-e285, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29778693